Study of markers of apoptosis, proliferation, and angiogenesis in patients ovarian cancer treated with accompanying immunotherapy
https://doi.org/10.18027/2224-5057-2017-1-84-90
Abstract
The aim of the work was to study a number of molecular biological tumor markers as selection criteria methods of accompanying extracorporeal immunopharmacotherapy
(EIFT) in patients with ovarian cancer (OC). The object of the study were 30 patients with OC with II–III clinical stages of the disease who were treated in gynecological cancer RORC MoH Uzbekistan office from 2009 to 2011 years and treated with standard combination therapy. Most of the patients with OC (83.3, 86.7 and 80.0%, respectively) were present molecular biological markers p53, VEGF and Ki‑67. At the same time, the
markers HER‑2/neu and EGFR were found in 20.0% of patients and 30.0 respectively. It is shown that the greatest prognostic value regarding the efficacy of the treatment of patients with OC have tumor markers p53, VEGF and Ki‑67, and the level of proliferative activity (PA) of the tumor. The greatest effect in increasing the 5-year survival of patients immunotherapy has provided the accompanying diagram including EIFT with
plasmapheresis. Positive okomarkerov level of p53, VEGF and Ki‑67 in patients with OC, along with high PA tumors can serve as a basis for this category of patients with immunotherapy accompanying EIFT. In the case of positive values of all the above molecular biological factors, we recommend carrying out the accompanying EIFT with plasmapheresis, which can significantly increase the effectiveness of standard anticancer
treatment schemes.
(EIFT) in patients with ovarian cancer (OC). The object of the study were 30 patients with OC with II–III clinical stages of the disease who were treated in gynecological cancer RORC MoH Uzbekistan office from 2009 to 2011 years and treated with standard combination therapy. Most of the patients with OC (83.3, 86.7 and 80.0%, respectively) were present molecular biological markers p53, VEGF and Ki‑67. At the same time, the
markers HER‑2/neu and EGFR were found in 20.0% of patients and 30.0 respectively. It is shown that the greatest prognostic value regarding the efficacy of the treatment of patients with OC have tumor markers p53, VEGF and Ki‑67, and the level of proliferative activity (PA) of the tumor. The greatest effect in increasing the 5-year survival of patients immunotherapy has provided the accompanying diagram including EIFT with
plasmapheresis. Positive okomarkerov level of p53, VEGF and Ki‑67 in patients with OC, along with high PA tumors can serve as a basis for this category of patients with immunotherapy accompanying EIFT. In the case of positive values of all the above molecular biological factors, we recommend carrying out the accompanying EIFT with plasmapheresis, which can significantly increase the effectiveness of standard anticancer
treatment schemes.
About the Authors
S. V. KAMYSHOV
National Cancer Research Center of the Ministry of Health of the Republic of Uzbekistan
Uzbekistan
MD, PhD, senior researcher
Uzbekistan
MD, PhD, senior researcher
D. A. NISHANOV
National Cancer Research Center of the Ministry of Health of the Republic of Uzbekistan
Uzbekistan
MD, PhD, head of department of pathomorphology
Uzbekistan
MD, PhD, head of department of pathomorphology
D. A. PULATOV
National Cancer Research Center of the Ministry of Health of the Republic of Uzbekistan
Uzbekistan
MD, PhD, DSc, professor, scientific director of I and II departments of chemotherapy
Uzbekistan
MD, PhD, DSc, professor, scientific director of I and II departments of chemotherapy
N. Sh. YULDASHEVA
National Cancer Research Center of the Ministry of Health of the Republic of Uzbekistan
Uzbekistan
MD, PhD, DSc, scientific director of Department of oncogynecology
Uzbekistan
MD, PhD, DSc, scientific director of Department of oncogynecology
References
1. de la Torre F. J., Garcia A., Gil-Moreno A., Planaguma J.,Reven-tos J., Ramon y Cajal S., Xercavins J. Apoptosis in epithelial ovarian tumors Prognostic significance of clinical and histopathologic factors and its association with the immuno-histochemical expression of apoptotic regulatory proteins (p53, bcl‑2 and bax) // Eur. J. Obstet. Gynecol. Reprod. Biol. –2007. – Vol. 130, N1. – P. 121–128.
2. Khouja M. H., Baeke-landt M., Nesland J. M., Holm R. The clinical importance of Ki‑67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma // Int. J. Gynecol. Pathol. –2007. – Vol. 26, N4. – P. 418–425.
3. Schindlbeck C., Hantschmann P., Zerzer M., Jahns B., Rjosk D., Janni W., Rack B. et al. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nrn23 expression of ovarian carcinomas and disseminated tumor cells in the bone мarrow // Int. J. Gynecil. Cancer. –2007. – V.17. – N5. – P. 1047–1055.
4. Imyanitov Ye.N. Molekulyarnye narusheniya v opukholyakh yaichnikov [Molecular disorders in ovarian tumors]. In book: Gorbunova V. A. Diagnostika i lechenie raka yaichnikov [Diagnosis and treatment of ovarian cancer]. – Moscow: Meditsinskoe informatsionnoe agentstvo [Medical News Agency], 2011. – P. 15–28.
5. Nikogosyan S. O., Kuznetsov V. V. Rak yaichnikov: voprosy diagnostiki i sovremennye metody lecheniya [Ovarian cancer: questions of diagnostics and modern methods of treatment] // Vrach [Doctor]. –2010. – N9. – P. 2–9.
6. Kommoss S., Rochon J., Harter P., Heitz F., Grabowski J. P., Ewald-Riegler N., Haberstroh M. et al. Prognostic impact of extended surgical procedures in advanced-stage primary ovarian cancer // Ann. Surg. Oncol. –2010. – V.17. – N1. – P. 279–286.
7. Curtsinger J. M., Gerner M. Y., Lins D. C., Mescher M. F. Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor // Journal of Immunology. –2007. – V. 178. – P. 6752–6760.
8. Rosenberg S., Restifo N., Yang J., Morgan R., Dudley M. Adoptive cell transfer a clinical path to effective cancer immunotherapy // Nature Reviews Cancer. –2008. – N8. – P. 299–308.
9. Chumakov P. M. Belok p53 i ego universalnye funktsii v mnogokletochnom organizme [The protein p53 and its universal function in a multicellular organism] // Uspekhi biologicheskoi khimii [Advances of Biological Chemistry]. –2007. – V.47. – N3. – P. 52.
10. Sylvia M. T., Kumar S., Dasari P. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her‑2-neu, p53 and Ki‑67 in epithelial ovarian tumors and its correlation with clinicopathologic variables // Pathology & Microbiology. –2012. – V.55. – N1. – P. 33–37.
11. Hoopmann M., Sachse K., Valter M. M., Becker M., Neumann R., Ortmann M., G hring U. J. et al. Serological and immunohistochemical HER‑2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients // Eur. J. Cancer. –2010. – V.19. – P. 809–815.
12. Le Page C., Huntsman D. G., Provencher D. M., Mes-Masson A. M. Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies // Cancer. –2010. – N2. – P. 913–954.
13. McAlpine J.N., Wiegand K. C., Vang R., Ronnett B. M., Adamiak A., K bel M., Kalloger S. E. et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy // BMC Cancer. –2009. – V.9. – P. 433.
14. Han C. P., Hsu J. D., Yao C. C., Lee M. Y., Ruan A., Tyan Y. S., Yang S. F. et al. HER2 gene amplification in primary mucinous ovarian cancer: a potential therapeutic target // Histopathology. –2010. – V. 57. – N5. – P. 763–764.
15. Tan D. S., Iravani M., McCluggage W.G., Lambros M. B., Milanezi F., Mackay A., Gourley C. et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas // Clin. Cancer. Res. –2011. – V.17. – N6. – P. 1521–1534.
16. Shanazarov N. A., Sabirov A. Kh., Sirotkina S. M. Rol epidermalnogo faktora rosta i ego retseptora v kantserogneze: molekulyarnye mekhanizmy ikh deystviya [The role of the epidermal growth factor and its receptor in kantserogneze: molecular mechanisms of action] // Russian Journal of biotherapeutic. –2009. – V.8. – N4. – P. 85–90.
17. Yarden Y. The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities // Eur. J. Cancer. –2001. – V.37. – N4. – P. 3–8.
18. Song X., Shi B., Huang K., Zhang W. miR‑133a inhibits cervical cancer growth by targeting EGFR // Oncol. Rep. –2015. – V. 34. – N3. – P. 1573–1580.
19. Ferrara N., Gerber H. P., LeCouter J. The biology of VEGF and its receptors // Nat. Med. –2003. – N9. – Р.669–676.
20. Ribatti D. History of research on tumor angiogenesis. – Netherlands, 2009. – 125 р.
Review
For citations:
KAMYSHOV S.V., NISHANOV D.A., PULATOV D.A., YULDASHEVA N.Sh. Study of markers of apoptosis, proliferation, and angiogenesis in patients ovarian cancer treated with accompanying immunotherapy. Malignant tumours. 2017;(1):84-90. (In Russ.) https://doi.org/10.18027/2224-5057-2017-1-84-90
Views:
1008
Email this article 